Optos is a world-leading manufacturer of retinal imaging technology to eyecare professionals. Its products, which are designed and manufactured at its headquarters in Fife, support the prevention of vision loss by helping to find signs of disease sooner.
It was founded in 1992 by Douglas Anderson who, following his young son going blind in one eye after suffering from a retinal detachment, set out to create a simple, patient-friendly retinal imaging product.
Optos is the only company in the world that can provide ultra-widefield (UWF™) technology to examine the periphery of the retina, where the early signs of disease and sight loss can be found.
Its devices can capture a 200-degree view, or 82%, of the retina, where competitor products typically only capture up to 60-degrees. This is achieved in a single, non-contact UWF image in less than half a second.
Now a three-time Queen’s Awards winner, having previously received the Queen’s Award for Enterprise in International Trade in 2007 and 2001, this year Optos has been awarded for its innovation with the design of an imaging device called California.
Optos has a very strong market position, particularly in the optometry market with its Daytona device. Optos developed the California device to expand the functionality offered, and so provide an enhanced technology that would meet the exact needs of ophthalmologists and optometrists.
The California offers UWF technology that is supported by data collected from 650 clinical studies, demonstrating the importance of imaging the retinal periphery to identify diseases and manage diagnoses.
The product’s innovative optical design provides high resolution images showing fine detail, whether viewing 200-degrees of the retina, or zoomed to inspect sections in even greater detail. The technology found in the California has been the catalyst for putting Optos at the forefront of the retinal imaging market.
Along with its technological capabilities, it was important that the California’s design and features fitted with the needs of Optos’ future customers and their patients.
The Optos engineering team designed a configurable device featuring new modalities, high-resolution images that were easy use and great value. It is available in three models with six imaging modalities, making it adaptable to the needs and budgets of every eye clinic.
The image quality was further enhanced to make it clearer for customers so they can better educate patients on any potential problems or diseases identified. The design also allows for older patients and children to move into the desired imaging position with ease, improving both the patient experience and the quality of image.
This gives customers peace of mind knowing that everything is being captured, and means any potential problems can be found.
What do customers really think?
Customers have reported an enhanced level of patient care from using California. They can now identify diseases and issues that previously went unnoticed, therefore reducing the risk of patient vision loss.
With images now taking less time to capture, an improvement in practice efficiency has also been reported.
One testimonial from a UK consultant ophthalmologist and vitreoretinal surgeon lays out the benefits of this technology first-hand: “Having California as part of our diagnostic armamentarium allows us to diagnose and treat patients more confidently and sometimes even at an earlier stage,” says Prof. Paulo E Stanga, Consultant Ophthalmologist and Vitreoretinal Surgeon at Manchester Royal Eye Hospital.
This Optos innovation is saving the sight of patients, improving practice efficiency and giving customers across the world reassurance that they are receiving the most advanced care possible in the fight against vision loss.